Gemcitabine PhaRes1 gm/vial

Gemcitabine PhaRes 1 gm/vial is an intravenous chemotherapy medicine used, as part of an oncologist-directed treatment plan, for:

• First-line treatment, in combination with cisplatin, for inoperable, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
• First-line treatment, as a single agent, for locally advanced or metastatic adenocarcinoma of the pancreas, including in patients previously treated with fluorouracil
• Treatment, in combination with carboplatin, for advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy
• First-line treatment, in combination with paclitaxel, for metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated

This medicine is administered only under the supervision of a qualified oncology specialist as part of a defined chemotherapy protocol.

Contains Gemcitabine PhaRes 1 gm/vial (as Gemcitabine PhaRes 1 gm/vial hydrochloride) for intravenous infusion. It is supplied either as a ready-to-use solution (commonly 38 mg/mL, in various vial sizes) or as a lyophilized powder for reconstitution (commonly 200 mg, 1 g, or 2 g single-dose vials). Exact presentations vary by manufacturer.

Gemcitabine PhaRes 1 gm/vial is a cytotoxic chemotherapy medicine given by intravenous infusion, used in the treatment of several cancers, including pancreatic, non-small cell lung, ovarian, and breast cancer, typically in combination with other chemotherapy agents. It works by interfering with the DNA synthesis of rapidly dividing cancer cells, which slows or stops tumor growth. Because of its potential for serious toxicity, Gemcitabine PhaRes 1 gm/vial is administered only under the close supervision of an oncology specialist, with regular blood count monitoring.

Therapeutic Class: Antineoplastic (Chemotherapy) Agent

Gemcitabine PhaRes 1 gm/vial is a prodrug that is taken up by cells and phosphorylated intracellularly to its active diphosphate and triphosphate metabolites. It exhibits cell-cycle phase specificity, primarily killing cells undergoing DNA synthesis and blocking the progression of cells through the G1/S phase boundary. Myelosuppression (reduced blood cell counts) is the principal dose-limiting toxicity, and Gemcitabine PhaRes 1 gm/vial is associated with transient elevation of liver transaminases in a large proportion of patients.

• Administered only by intravenous infusion over 30 minutes, by trained oncology healthcare professionals
• Longer infusion times and more frequent dosing than recommended have been associated with increased toxicity
• Complete blood counts are checked before each dose, and treatment is delayed or the dose modified if blood counts are too low
• Prepared and administered following institutional protocols for handling cytotoxic (chemotherapy) medicines

The following should be assessed and managed by the treating oncology team before or during Gemcitabine PhaRes 1 gm/vial treatment:

• Other chemotherapy agents given in combination (such as cisplatin, carboplatin, or paclitaxel), where dosing and scheduling are specifically coordinated as part of the combination regimen
• Radiation therapy, since combining Gemcitabine PhaRes 1 gm/vial with radiation can increase the risk of significant toxicity; timing is carefully planned by the treating team
• Live vaccines, which should generally be avoided during chemotherapy due to immune suppression

Common side effects

• Nausea and vomiting
• Fatigue
• Fever
• Elevated liver enzymes (transient, in the majority of patients)
• Rash
• Hair thinning
• Constipation or diarrhoea

Serious side effects (require prompt medical attention)

• Myelosuppression: signs of low blood counts, such as unusual bruising or bleeding, fever, or signs of infection
• Severe cutaneous adverse reactions (SCARs), such as widespread blistering or peeling skin - requires permanent discontinuation
• Pulmonary toxicity: new or worsening shortness of breath, cough
• Signs of capillary leak syndrome or posterior reversible encephalopathy syndrome (rare but serious)
• Signs of haemolytic uremic syndrome: unusual bruising, decreased urination, confusion
• Signs of liver failure (rare but serious): yellowing of the skin or eyes, severe abdominal pain

Pregnancy

Based on its mechanism of action and animal data, Gemcitabine PhaRes 1 gm/vial can cause fetal harm and is teratogenic, embryotoxic, and fetotoxic in animal studies. It should not be used during pregnancy; effective contraception is recommended for patients of reproductive potential during treatment and for a period afterward, as advised by the treating oncologist.

Breastfeeding

It is not known whether Gemcitabine PhaRes 1 gm/vial passes into human milk; breastfeeding is generally not recommended during treatment and for a period afterward, given the potential for serious adverse effects in a nursing infant.

• Myelosuppression: The principal dose-limiting toxicity; complete blood counts are monitored before each dose, and treatment is adjusted or delayed for significant reduction in blood cell counts.
• Pulmonary toxicity: Serious pulmonary effects, including pulmonary edema and adult respiratory distress syndrome, have been reported; treatment is generally discontinued if severe pulmonary toxicity develops.
• Renal toxicity: Haemolytic uremic syndrome and other severe renal effects have been reported; monitor renal function during treatment.
• Hepatotoxicity: Serious liver toxicity, including liver failure, has been reported rarely; liver function is monitored during treatment.
• Severe cutaneous adverse reactions: Permanently discontinue if these occur.
• This medicine should only be administered by, or under the direct supervision of, a physician experienced in the use of cancer chemotherapeutic agents.

There is no known antidote for Gemcitabine PhaRes 1 gm/vial overdose. Overdose would be expected to worsen the known toxicities, particularly myelosuppression (low blood counts), and would require intensive supportive care, including blood count monitoring and, where clinically indicated, transfusion support and treatment of any resulting infection, under the direct management of the oncology treatment team.

Store unopened vials at controlled room temperature, as directed on the product label. Do not freeze. Reconstituted or diluted solutions should be used within the manufacturer's specified time frame, and unused reconstituted solution should not be refrigerated, as this may cause crystallization; follow the specific product's handling and stability instructions, and dispose of unused cytotoxic medicine according to institutional protocols for hazardous pharmaceutical waste.

• Elderly: Used with the same weight-based dosing approach, with careful monitoring of blood counts and organ function, as age-related decline in these may increase toxicity risk.
• Renal or hepatic impairment: Use with caution and close monitoring, as Gemcitabine PhaRes 1 gm/vial clearance and toxicity may be affected; specific dose adjustment should be determined by the treating oncologist.

Treatment continues in cycles for as long as the cancer responds and the patient tolerates therapy, as determined by the treating oncologist based on periodic reassessment of disease response and toxicity. There is no fixed universal duration; treatment plans are individualized to the specific cancer, combination regimen, and patient's clinical course.

The lyophilized powder form must be reconstituted with the diluent specified by the manufacturer (commonly 0.9% sodium chloride injection without preservative) immediately before use, following the specific product's instructions for volume and resulting concentration (commonly targeting approximately 38 mg/mL or less). Reconstituted solution should be used promptly per the manufacturer's stability data and should not be refrigerated, as crystallization may occur; unused portions should be discarded according to institutional cytotoxic waste handling procedures.

Drug Class: Pyrimidine antimetabolite (nucleoside analogue)

Once inside cancer cells, Gemcitabine PhaRes 1 gm/vial is converted to active metabolites that are incorporated into DNA in place of normal building blocks. This disrupts DNA synthesis and repair in rapidly dividing cells, ultimately triggering cell death (apoptosis) in cancer cells that are actively dividing, which slows tumor growth.

Gemcitabine PhaRes 1 gm/vial is primarily used in adult oncology practice for the cancers listed under indications; established pediatric dosing and safety data are limited, and any pediatric use would only occur under specialist pediatric oncology supervision as part of a specific treatment protocol.